I. Márquez-Rodas

发表

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

D. Schadendorf, P. Ascierto, R. Dummer, 2017, The New England journal of medicine.

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

D. Schadendorf, P. Ascierto, R. Dummer, 2019, The New England journal of medicine.

Neurogenic nitric oxide release increases in mesenteric arteries from ouabain hypertensive rats.

G. Balfagón, I. Márquez-Rodas, D. Vassallo, 2004 .

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Dirk Schadendorf, Reinhard Dummer, Paolo A Ascierto, 2015, The New England journal of medicine.

Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit

Miguel Martín, M. Cebollero, I. Márquez-Rodas, 2018, Journal of Genetic Counseling.

Evaluation of a Heredofamilial Cancer Unit in Increasing Family History Collection and Genetic Counseling Referrals Among Spanish Oncologists at a University Hospital

Miguel Martín, A. Rupérez, I. Márquez-Rodas, 2014, Journal of Genetic Counseling.

Family History Record and Hereditary Cancer Risk Perception according to National Cancer Institute Criteria in a Spanish Medical Oncology Service: A Retrospective Study

Miguel Martín, F. Calvo, I. Márquez-Rodas, 2012, Oncology.

Deregulated miRNAs in Hereditary Breast Cancer Revealed a Role for miR-30c in Regulating KRAS Oncogene

J. Benítez, A. Osorio, B. Martínez-Delgado, 2012, PloS one.

Review: circulating tumor cells in the practice of breast cancer oncology

M. Martín, J. García-Saenz, F. Moreno, 2016, Clinical and Translational Oncology.

Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients

R. Rosell, A. Giménez-Capitán, N. Karachaliou, 2018, Therapeutic advances in medical oncology.

ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee

B. Schilling, S. Puig, V. Sondak, 2020 .

Long-term fenofibrate treatment impairs endothelium-dependent dilation to acetylcholine by altering the cyclooxygenase pathway.

J. Blanco-Rivero, G. Balfagón, I. Márquez-Rodas, 2007, Cardiovascular research.

Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts

J. García-Saenz, F. Moreno, Miguel Martín, 2020, Scientific Reports.

MicroRNA expression signatures for the prediction of BRCA1/2 mutation‐associated hereditary breast cancer in paraffin‐embedded formalin‐fixed breast tumors

J. Benítez, D. Pisano, A. Osorio, 2014, International journal of cancer.

Circulating tumor cells following first chemotherapy cycle: an early and strong predictor of outcome in patients with metastatic breast cancer.

J. García-Saenz, Miguel Martín, E. Díaz-Rubio, 2013, The oncologist.

Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172).

D. Schadendorf, P. Ascierto, R. Dummer, 2019, European journal of cancer.

Prognostic significance of sentinel node biopsy status in cutaneous melanoma: a 21-years prospective study from a single institution

I. Márquez-Rodas, E. Mercader-Cidoncha, J. Avilés-Izquierdo, 2020, Clinical and Translational Oncology.

Why do patients with thick melanoma have different outcomes? A retrospective epidemiological and survival analysis

I. Márquez-Rodas, E. Rodríguez-Lomba, R. Suárez-Fernández, 2017, Clinical and Translational Oncology.

Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma – Prima study

J. Malvehy, V. Guillem, E. Espinosa, 2016, Melanoma research.

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

P. Ascierto, J. Larkin, M. Atkins, 2017, The New England journal of medicine.

Participation of Prostacyclin in Endothelial Dysfunction Induced by Aldosterone in Normotensive and Hypertensive Rats

J. Blanco-Rivero, V. Cachofeiro, V. Lahera, 2005, Hypertension.

Melanoma proteomics suggests functional differences related to mutational status

E. Espinosa, C. Fortes, L. Trilla-Fuertes, 2019, Scientific Reports.

Melanoma proteomics unravels major differences related to mutational status

E. Espinosa, C. Fortes, L. Trilla-Fuertes, 2017, bioRxiv.

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

Michael F. Sharpnack, D. Schadendorf, R. Sullivan, 2018, Journal of Translational Medicine.

Cirrhosis decreases vasoconstrictor response to electrical field stimulation in rat mesenteric artery: role of calcitonin gene‐related peptide

F. Perez-Vizcaino, J. Blanco-Rivero, I. Márquez-Rodas, 2011, Experimental physiology.

Neurogenic nitric oxide release increases in mesenteric arteries from ouabain hypertensive rats

I. Márquez-Rodas, D. Vassallo, L. Rossoni, 2004, Journal of hypertension.

Pathophysiology and therapeutic possibilities of calcitonin gene-related peptide in hypertension

I. Márquez-Rodas, R. Rothlin, G. Balfagón, 2006, Journal of Physiology and Biochemistry.

Frequency and Characteristics of Familial Melanoma in Spain: The FAM-GEM-1 Study

A. Arance, V. Soriano, E. Nagore, 2015, PloS one.

CCL20 Expression by Tumor-Associated Macrophages Predicts Progression of Human Primary Cutaneous Melanoma

R. Samaniego, M. Relloso, I. Márquez-Rodas, 2018, Cancer Immunology Research.

Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations

Miguel Martín, I. Márquez-Rodas, S. López-Tarruella, 2019, Drugs.

ESMO consensus conference recommendations on the management of locoregional melanoma: the ESMO Guidelines Committee.

B. Schilling, S. Puig, V. Sondak, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors

I. Melero, M. Rodriguez-Ruiz, P. López-Casas, 2020, Science Translational Medicine.

Metastatic Melanoma with Spontaneous Regression, Psoriasis and HLA-Cw6: Case Report and a Hypothesis to Explore

Miguel Martín, J. Vicario, I. Márquez-Rodas, 2014, Tumori.

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination

A. Carneiro, G. Long, L. Ny, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA66_PR Disparities in access to oncology clinical trials in Europe in the period 2009-2019

T. Amaral, G. Morgan, L. Mezquita, 2020 .

Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.

P. Ascierto, J. Larkin, A. Arance, 2020, The Lancet. Oncology.

ESMO consensus conference recommendations on the management of metastatic melanoma: the ESMO Guidelines Committee.

B. Schilling, S. Puig, V. Sondak, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee

B. Schilling, S. Puig, V. Sondak, 2020 .

Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.

D. Schadendorf, R. Dummer, J. Wolchok, 2022, Journal of Clinical Oncology.

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

D. Schadendorf, P. Ascierto, R. Dummer, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma.

R. García-Carbonero, J. Capdevila, E. Grande, 2019, The oncologist.

Understanding the Lived Experiences of Patients With Melanoma: Real-World Evidence Generated Through a European Social Media Listening Analysis

A. Forschner, L. Formisano, G. Faust, 2021, JMIR cancer.

Understanding the Lived Experience of Patients with Melanoma: Real-World Evidence Generated through a European Social Media Listening Analysis (Preprint)

A. Forschner, L. Formisano, G. Faust, 2021 .

Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.

P. Ascierto, A. Arance, P. Queirolo, 2022, European journal of cancer.

Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.

Miguel Martín, I. Márquez-Rodas, S. López-Tarruella, 2017, Future oncology.

Aldosterone modulates neural vasomotor response in hypertension: role of calcitonin gene-related peptide

V. Cachofeiro, V. Lahera, I. Márquez-Rodas, 2004, Regulatory Peptides.

1213OCharacterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone

D. Schadendorf, P. Ascierto, J. Wolchok, 2017 .

Venous thromboembolism incidence in cancer patients with germline BRCA mutations

M. Martín, I. Márquez-Rodas, A. Muñoz, 2021, Clinical and Translational Oncology.

COVID-19 in melanoma patients: Results of the Spanish Melanoma Group Registry, GRAVID study

S. Puig, R. Rosell, M. Provencio, 2021, Journal of the American Academy of Dermatology.

Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial

P. Ascierto, A. Arance, M. Mandalà, 2019, Annals of Oncology.

Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238)

P. Ascierto, J. Larkin, A. Arance, 2017 .

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.

D. Schadendorf, R. Dummer, J. Wolchok, 2018, The Lancet. Oncology.

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.

K. Savage, J. Wolchok, J. Larkin, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Aldosterone increases RAMP1 expression in mesenteric arteries from spontaneously hypertensive rats

J. Blanco-Rivero, I. Márquez-Rodas, R. Aras-López, 2006, Regulatory Peptides.

[Perivascular innervation of the superior mesenteric artery: pathophysiological implications].

J. Blanco-Rivero, I. Márquez-Rodas, G. Balfagón, 2010, Revista de neurologia.

Protein kinase A increases electrical stimulation-induced neuronal nitric oxide release in rat mesenteric artery.

I. Márquez-Rodas, M. Salaices, M. Alonso, 2004, European journal of pharmacology.

Pitfalls on Screening in Clinical Trials: Positive Pregnancy Test in a Nonpregnant Woman with Metastatic Breast Cancer

Yol, A. Jerez, Miguel Martín, 2014 .

Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

I. Melero, M. Rodriguez-Ruiz, J. Pérez-Gracia, 2019, Nature.

MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours

J. Benítez, A. Osorio, B. Martínez-Delgado, 2013, British Journal of Cancer.

Cyclin Kinase Inhibitors in Breast Cancer: From Bench to Bedside

Miguel Martín, I. Márquez-Rodas, M. Lobo, 2014, Current Breast Cancer Reports.

Immunotherapeutic effects of intratumoral nanoplexed poly I:C

I. Melero, M. Rodriguez-Ruiz, P. López-Casas, 2019, Journal of Immunotherapy for Cancer.

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

D. Schadendorf, P. Ascierto, M. Smylie, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neratinib (HKI-272) in the treatment of breast cancer.

Miguel Martín, I. Márquez-Rodas, S. López-Tarruella, 2012, Future oncology.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, A. Hauschild, J. Malvehy, 2016, Journal of Translational Medicine.

Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts

C. Perou, A. Picornell, H. Gómez, 2016, Clinical Cancer Research.

Predictive factors of response to immunotherapy-a review from the Spanish Melanoma Group (GEM).

Enrique Espinosa, E. Espinosa, I. Márquez-Rodas, 2017, Annals of translational medicine.

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials

D. Schadendorf, R. Dummer, J. Wolchok, 2017, JAMA oncology.

CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.

D. Schadendorf, R. Dummer, J. Wolchok, 2021 .

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

Ying Zhang, Jean-Jacques Grob, Keith T Flaherty, 2017, The Lancet. Oncology.

Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program

A. Arance, E. Espinosa, C. Montagut, 2017, Clinical and Translational Oncology.

Immune checkpoint inhibitors: therapeutic advances in melanoma.

I. Márquez-Rodas, A. Berrocal, A. Soria, 2015, Annals of translational medicine.

Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel

C. Perou, A. Picornell, H. Gómez, 2018, Clinical Cancer Research.

The Implementation of a Multidisciplinary Heredofamilial Cancer Unit Changes Hereditary Cancer Risk Perception among Oncologists

I. Márquez-Rodas, S. López-Tarruella, Y. Jerez, 2012 .

Genomic Studies in Cancer: Ready for Use?

I. Márquez-Rodas, 2012 .

Exclusion Criteria vs Reality: Dual BRAF/MEK Inhibition and Radiotherapy in a Patient with Melanoma Metastatic to the Brain and ECOG 3

Miguel Martín, I. Márquez-Rodas, P. Borrego, 2016, Tumori.

Dabrafenib plus trametinib for compassionate use in metastatic melanoma

A. Arance, V. Soriano, L. Fernández-Morales, 2017, Medicine.

Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

I. Melero, M. Rodriguez-Ruiz, J. Pérez-Gracia, 2019, Nature.

Supervised physical exercise improves VO2max, quality of life, and health in early stage breast cancer patients: a randomized controlled trial

R. Newton, D. Galvão, J. Sampedro, 2015, Breast Cancer Research and Treatment.

The RANK–RANKL axis: an opportunity for drug repurposing in cancer?

C. Gedye, P. Clézardin, I. Márquez-Rodas, 2019, Clinical and Translational Oncology.

[Melanoma of male urethra: A clinical case].

A. M. Muñoz Martín, I. Márquez-Rodas, L. Cabezón Gutiérrez, 2010, Actas Urológicas Españolas.

A retrospective chart review study describing metastatic melanoma patients profile and treatment patterns in Spain

A. Arance, A. Berrocal, I. Márquez-Rodas, 2019, Clinical and Translational Oncology.

Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial

A. Picornell, H. Gómez, J. García-Saenz, 2016, Breast Cancer Research and Treatment.

SEOM clinical guideline for the management of malignant melanoma (2017)

A. Arance, E. Espinosa, I. Márquez-Rodas, 2017, Clinical and Translational Oncology.

Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer

J. García-Saenz, F. Moreno, Miguel Martín, 2017, Breast Cancer Research and Treatment.

CheckMate 067: Long-term outcomes in patients with mucosal melanoma.

P. Ascierto, R. Dummer, J. Larkin, 2020 .

Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience

M. Martín, J. García-Saenz, J. A. Guerra Martínez, 2019, Clinical and Translational Oncology.

SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry

S. Puig, M. Provencio, J. Gardeazabal, 2022, Clinical and Translational Oncology.

Deletion at 6q24.2–26 predicts longer survival of high‐grade serous epithelial ovarian cancer patients

J. Cigudosa, M. Urioste, J. Benítez, 2014, Molecular oncology.

SEOM clinical guideline for the management of cutaneous melanoma (2020)

E. Espinosa, I. Márquez-Rodas, L. de la Cruz-Merino, 2021, Clinical and Translational Oncology.

Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).

D. Schadendorf, P. Ascierto, R. Dummer, 2019, European journal of cancer.

Efficacy and safety of immune checkpoint inhibitor immunotherapy in elderly cancer patients

M. Martín, I. Márquez-Rodas, B. Fox, 2019, Clinical and Translational Oncology.

CCL20/TNF/VEGFA Cytokine Secretory Phenotype of Tumor-Associated Macrophages Is a Negative Prognostic Factor in Cutaneous Melanoma

A. Puig-Kröger, R. Samaniego, M. Fernández-Santos, 2021, Cancers.

A new era in the treatment of melanoma: from biology to clinical practice

Miguel Martín, I. Márquez-Rodas, J. Izquierdo, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, Ludmila V. Danilova, David C. Smith, 2016, Journal of Translational Medicine.

5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma

D. Schadendorf, R. Dummer, J. Wolchok, 2019, Annals of Oncology.

Five Years of Multidisciplinary Care in Hereditary Cancer: Our Experience in a Spanish University Hospital

M. Martín, I. Márquez-Rodas, M. Lobo, 2016, Oncology.

Running away from side effects: physical exercise as a complementary intervention for breast cancer patients

M. Martín, R. Barakat, Miguel Martín, 2015, Clinical and Translational Oncology.

Neratinib for the treatment of HER2-positive early stage breast cancer

Miguel Martín, I. Márquez-Rodas, S. López-Tarruella, 2017, Expert review of anticancer therapy.

Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma.

D. Schadendorf, S. Ugurel, R. Sullivan, 2022, European journal of cancer.

J. Benítez, S. Borrego, L. Paz-Ares, 2015, Journal of gynecologic oncology.

Epidemiological changes in cutaneous melanoma: retrospective study of 969 cases (1996-2010).

I. Márquez-Rodas, V. Parra-Blanco, R. Suárez-Fernández, 2013, Revista clinica espanola.

Who detects melanoma? Impact of detection patterns on characteristics and prognosis of patients with melanoma.

I. Márquez-Rodas, E. Rodríguez-Lomba, R. Suárez-Fernández, 2016, Journal of the American Academy of Dermatology.

Concordance of Genomic Variants in Matched Primary Breast Cancer, Metastatic Tumor, and Circulating Tumor DNA: The MIRROR Study.

A. Picornell, J. García-Saenz, F. Moreno, 2019, JCO precision oncology.

Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM “El Álamo III” retrospective study

A. Ruíz, S. González, R. Andrés, 2017, PloS one.

1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone

D. Schadendorf, P. Ascierto, J. Wolchok, 2020 .

For Whom the Cell Tolls? Intratumoral Treatment Links Innate and Adaptive Immunity

I. Melero, I. Márquez-Rodas, A. Calles, 2018, Clinical Cancer Research.

Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification

C. Perou, K. Hoadley, A. Picornell, 2018, Clinical Cancer Research.

Increased expression in calcitonin-like receptor induced by aldosterone in cerebral arteries from spontaneously hypertensive rats does not correlate with functional role of CGRP receptor

J. Blanco-Rivero, I. Márquez-Rodas, F. E. Xavier, 2008, Regulatory Peptides.

Primary ovarian Burkitt lymphoma

A. M. Muñoz Martín, I. Márquez-Rodas, P. García Alfonso, 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067).

D. Schadendorf, R. Dummer, J. Wolchok, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

Michael F. Sharpnack, D. Schadendorf, R. Sullivan, 2018, Journal of Translational Medicine.

LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004

A. Carneiro, G. Long, L. Ny, 2020 .

Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511).

P. Ascierto, M. Smylie, I. Svane, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Cancer immunotherapy does not increase the risk of death by COVID-19 in melanoma patients

S. Puig, R. Rosell, M. Provencio, 2020, medRxiv.

Melanoma proteomics suggests functional differences related to mutational status

E. Espinosa, C. Fortes, L. Trilla-Fuertes, 2019, Scientific Reports.

Abstract CT014: Efficacy of intratumoral BO-112 with systemic pembrolizumab in patients with advanced melanoma refractory to anti-PD-1-based therapy: Final results of SPOTLIGHT203 phase 2 study

A. Arance, Helena Escuin-Ordinas, S. Dalle, 2022, Cancer Research.

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

D. Schadendorf, P. Ascierto, M. Smylie, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemobrain: Can we consider an acquired brain injury from chemotherapy?

I. Márquez-Rodas, G. Chiclana, Ferre Navarrete, 2014 .

Genomic Profiling Tests Utility in the Management of Breast Cancer: The Adjuvant Setting as an Example

Yol, A. Jerez, Miguel Martín, 2013 .

1222PDRegional differences in overall survival (OS) in patients with advanced melanoma (MEL) who received nivolumab (NIVO) combined with ipilimumab (IPI) or NIVO alone in a phase 3 trial (CheckMate 067)

D. Schadendorf, P. Ascierto, J. Wolchok, 2017 .

1076O Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238

P. Ascierto, J. Larkin, M. Mandalà, 2020 .

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

P. Ascierto, A. Arance, P. Queirolo, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

85P Correlation between nCOUNTER PAM-50 assay and three IHC-based surrogate intrinsic breast cancer subtype classifiers: A real-world study

M. Cebollero, I. Márquez-Rodas, J. G. García Sáenz, 2022, Annals of Oncology.

Neratinib for the treatment of HER2-positive early stage breast cancer

Miguel Martín, I. Márquez-Rodas, S. López-Tarruella, 2017, Expert review of anticancer therapy.

Cirrhosis decreases vasoconstrictor response to electrical field stimulation in rat mesenteric artery: role of calcitonin gene‐related peptide

J. Blanco-Rivero, I. Márquez-Rodas, Á. Cogolludo, 2011, Experimental physiology.

Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study.

J. García-Saenz, M. Cebollero, I. Márquez-Rodas, 2023, Breast Cancer Research and Treatment.

Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.

A. Carneiro, A. Arance, G. Long, 2021, Journal of Clinical Oncology.